AXWAY
20.4.2016 08:01:53 CEST | Business Wire | Press release
Axway , a market leader in digital business enablement, is pleased to be the technology partner of Les Echos, the leading business and financial daily media in France, in support of its premier Hackathon event, “Hackapress des Echos ” in Paris, France. In less than 48 hours, 50 developers and designers in eight teams will compete to deliver the most innovative code that will better enable Les Echos’ use of data to enrich editorial work. With a successful track record enabling hackathons and other digital transformation initiatives, Axway will provide the digital platform for the event.
Today’s digital economy forces organizations to reinvent traditional business with innovative services. Many of them take advantage of hackathons to find new creative ways to provide better customer experiences and to build a digital culture between teams.
With the objective to reenergize the way Les Echos journalists work with their content in today’s digital age, “Hackapress des Echos” will help to forge connections between student developers, designers, and startups. Axway commits to innovation by supporting partners’ hackathon initiatives with API Management , providing technological means for hackathoners to utilize data intelligently to engage with their digital ecosystem, harvest information from data sources, and develop new methods for their projects.
“We are looking forward to seeing what creative and original projects the teams are able to develop, and this is exciting,” said Jeanine Banks, executive vice president, global products and solutions. “We believe that the future of digital business relies not only on APIs and other digital transformation technologies, but also the young minds of those who innovate.”
To stimulate and assist participants in preparing their projects, representatives from Les Echos (including journalists) will be present as mentors, observers, or participants. Teams will then present their projects at the conclusion of the event. The jury will be composed of Francis Morel, Chairman of Groupe Les Echos; Henri Gibier, Director of Editorials Developments Groupe Les Echos; Digital Village (start-ups and individuals freelancers specialize in digital); and Raise investment company.
The prize for winners, sponsored by Axway, will be presented by Francis Morel, and Bruno Patino (Director of the Journalism School of Sciences Po).
WHAT: Hackapress des Echos
WHEN: April 28-29, 2016
WHERE: Sciences Po Paris, 27 Rue Saint-Guillaume, 75007 Paris
PARTNERS OF HACKATHON DES ECHOS: Axway, Sciences Po, Digital Village, Digital Campus, Paris City Hall and Raise Endowment Fund
WHO: Students, freelancers, startups and observing outsiders
REGISTRATION: All attendees must register, here .
Follow Axway’s news on Twitter: @Axway #APIFirst #DigitalBusiness
About Axway
Axway (Euronext:AXW.PA) empowers more than 11,000 customers worldwide to collaborate smarter, innovate faster and engage better with their partners, developers and customers. From integration technology that securely connects people, processes and things to an engagement platform that enables API management, identity management, mobile app development and analytics, Axway solutions are enabling digital business. Axway is registered in France with headquarters in the United States. More information is available at: www.axway.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160419006912/en/
Contact:
Media
Neil Desai, 415-856-5150
Blanc & Otus
neil.desai@blancandotus.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom